Inhibitor of DNA binding-1 is a key regulator of cancer cell vasculogenic mimicry.
| Title: | Inhibitor of DNA binding-1 is a key regulator of cancer cell vasculogenic mimicry. |
|---|---|
| Authors: | Thompson EJ; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; Dorward EL; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; Jurrius K; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; Nataren N; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; Tondl M; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; Myo Min KK; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; Cockshell MP; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; Fouladzadeh A; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; Toubia J; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; ACRF Cancer Genomics Facility, Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; DeNichilo M; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; Merino D; Olivia Newton John Cancer Research Institute, Melbourne, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Australia.; Department of Medical Biology, The Faculty of Medicine, Dentistry and Health Science, The University of Melbourne, Australia.; Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.; Bonder CS; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, Australia.; Adelaide Medical School, University of Adelaide, Australia. |
| Source: | Molecular oncology [Mol Oncol] 2025 Sep; Vol. 19 (9), pp. 2537-2556. Date of Electronic Publication: 2025 Mar 21. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2017- : Hoboken, New Jersey : John Wiley & Sons, Inc.; Original Publication: Amsterdam : Elsevier |
| MeSH Terms: | Inhibitor of Differentiation Protein 1*/metabolism ; Inhibitor of Differentiation Protein 1*/genetics ; Neovascularization, Pathologic*/genetics ; Neovascularization, Pathologic*/metabolism ; Neovascularization, Pathologic*/pathology ; Breast Neoplasms*/pathology ; Breast Neoplasms*/genetics ; Breast Neoplasms*/blood supply ; Breast Neoplasms*/metabolism; Humans ; Animals ; Female ; Cell Line, Tumor ; Mice ; Gene Expression Regulation, Neoplastic |
| Abstract: | Solid tumours routinely access the blood supply by promoting endothelium-dependent angiogenesis; but tumour vasculature can also be formed by cancer cells themselves via vasculogenic mimicry (VM). Investigation of the gene expression profile during the early stages of VM formation by MDA-MB-231-LM2 breast cancer cells identified the transcriptional regulator inhibitor of DNA binding 1 (ID1) to be elevated ~ 10-fold within the first 2 hours. This role for ID1 in promoting VM was supported by ID1 genetic knockdown or chemical inhibition interrupting VM formation by MDA-MB-231-LM2 (breast) and BxPC-3 (pancreatic) cancer cells. More specifically, reducing ID1 lowered cancer cell expression of endothelial cell genes (e.g. CDH5, TIE2) and production of pro-angiogenic proteins (e.g. VEGF, CD31, MMP9 and IL-8). In silico analysis of MDA-MB-231 cells engrafted into mice identified elevated ID1 expression in cancer cells that had metastasised to the lungs or liver, and an enrichment of pro-angiogenic genes. Additionally, Id1 knockdown in 4T1.13 murine breast cancer cells demonstrated reduced tumour growth and metastasis in vivo. Taken together, this study further implicates ID1 in a vascular program within cancer cells that supports disease progression.; (© 2025 The Author(s). Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.) |
| References: | Front Oncol. 2019 Aug 02;9:680. (PMID: 31428573); Sci Rep. 2016 Nov 11;6:36659. (PMID: 27834402); Nat Biotechnol. 2008 Jan;26(1):91-100. (PMID: 18176556); Oncoimmunology. 2022 Mar 9;11(1):2043673. (PMID: 35295096); Int J Cancer. 2006 Apr 15;118(8):2072-81. (PMID: 16287090); Pharmacol Ther. 2016 Mar;159:83-92. (PMID: 26808163); JAMA Otolaryngol Head Neck Surg. 2013 Mar;139(3):273-8. (PMID: 23657791); Mol Cancer Res. 2005 Jan;3(1):1-13. (PMID: 15671244); Cell Rep. 2020 Apr 28;31(4):107572. (PMID: 32348770); Sci Adv. 2021 Jul 7;7(28):. (PMID: 34233875); Mol Cancer. 2017 Mar 21;16(1):65. (PMID: 28320399); J Histochem Cytochem. 2006 Aug;54(8):933-44. (PMID: 16651389); Nucleic Acids Res. 2022 Jul 5;50(W1):W216-W221. (PMID: 35325185); World J Oncol. 2019 Feb;10(1):10-27. (PMID: 30834048); Int J Med Sci. 2020 Apr 6;17(8):995-1005. (PMID: 32410828); Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9314-9. (PMID: 9256479); Mol Carcinog. 2021 Feb;60(2):151-163. (PMID: 33428809); Placenta. 2000 Sep;21(7):670-7. (PMID: 10985970); Nat Rev Cancer. 2003 Jun;3(6):411-21. (PMID: 12778131); Nature. 2005 Jul 28;436(7050):518-24. (PMID: 16049480); Mol Cancer. 2014 Sep 08;13:207. (PMID: 25200065); Cell Commun Signal. 2017 Jan 25;15(1):7. (PMID: 28122577); Angiogenesis. 2016 Apr;19(2):191-200. (PMID: 26899730); Nat Protoc. 2009;4(1):44-57. (PMID: 19131956); Cell. 2016 Mar 24;165(1):45-60. (PMID: 27015306); J Am Heart Assoc. 2023 Feb 21;12(4):e024303. (PMID: 36789992); Oncotarget. 2016 Jul 19;7(29):46492-46508. (PMID: 27340778); J Clin Invest. 2016 Jul 1;126(7):2689-705. (PMID: 27322059); Cancer Cell. 2012 Jan 17;21(1):11-24. (PMID: 22264785); Methods Mol Biol. 2016;1418:391-416. (PMID: 27008025); Cancer Manag Res. 2021 Jan 25;13:659-675. (PMID: 33536782); Eur J Cancer. 2013 Dec;49(18):3914-23. (PMID: 23992642); CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338); J Cell Biol. 1992 Nov;119(3):629-41. (PMID: 1383237); J Neurosurg. 1995 May;82(5):864-73. (PMID: 7714613); J Cell Biochem. 2008 Oct 1;105(2):562-73. (PMID: 18655191); Am J Pathol. 2002 Jan;160(1):195-204. (PMID: 11786413); Nucleic Acids Res. 2015 Jul 1;43(W1):W39-49. (PMID: 25953851); Sci Rep. 2020 Apr 3;10(1):5869. (PMID: 32246008); Cancer Cell. 2008 Oct 7;14(4):324-34. (PMID: 18835034); J Biol Chem. 2007 May 4;282(18):13769-79. (PMID: 17339326); Carcinogenesis. 2012 Apr;33(4):810-7. (PMID: 22301282); Oncol Lett. 2019 Dec;18(6):6741-6751. (PMID: 31807183); J Transl Med. 2013 Jan 11;11:13. (PMID: 23311395); Cancer Res. 2003 Sep 1;63(17):5381-9. (PMID: 14500372); Front Immunol. 2021 May 20;12:658097. (PMID: 34093545); Can J Urol. 2009 Aug;16(4):4726-32. (PMID: 19671223); Carcinogenesis. 2005 Oct;26(10):1668-76. (PMID: 15905202); Clin Transl Immunology. 2017 Mar 17;6(3):e134. (PMID: 28435677); Am J Pathol. 1999 Sep;155(3):739-52. (PMID: 10487832); Nat Med. 2001 Nov;7(11):1194-201. (PMID: 11689883); Angiogenesis. 2023 Nov;26(4):477-480. (PMID: 37640982); Bioinformatics. 2010 Jan 1;26(1):139-40. (PMID: 19910308); Science. 1989 Dec 8;246(4935):1306-9. (PMID: 2479986); Cancer Biol Ther. 2008 May;7(5):758-66. (PMID: 18376140); Nat Rev Cancer. 2014 Feb;14(2):77-91. (PMID: 24442143); Genome Res. 2002 Jun;12(6):996-1006. (PMID: 12045153); J Biomed Sci. 2018 Aug 8;25(1):62. (PMID: 30086759); J Clin Invest. 2006 Jun;116(6):1561-70. (PMID: 16741576); Cancer Cell. 2023 Mar 13;41(3):374-403. (PMID: 36917948); Cold Spring Harb Symp Quant Biol. 2005;70:149-58. (PMID: 16869748); Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886); Cell Rep. 2019 Oct 1;29(1):62-75.e7. (PMID: 31577956); Int J Oncol. 2006 Apr;28(4):847-54. (PMID: 16525633); Nature. 1999 Oct 14;401(6754):670-7. (PMID: 10537105); Placenta. 2012 Jul;33(7):586-8. (PMID: 22541610); Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204); Differentiation. 2006 Dec;74(9-10):481-7. (PMID: 17177845); Clin Cancer Res. 2003 Feb;9(2):779-85. (PMID: 12576450); Mol Cancer. 2021 Jan 4;20(1):7. (PMID: 33397409); Am J Transl Res. 2018 Dec 15;10(12):3887-3910. (PMID: 30662638); Nucleic Acids Res. 2013 Jan;41(Database issue):D56-63. (PMID: 23193274); Clin Cancer Res. 2021 May 1;27(9):2383-2393. (PMID: 33376096); Brief Bioinform. 2013 Mar;14(2):178-92. (PMID: 22517427); Nucleic Acids Res. 2022 Jan 7;50(D1):D165-D173. (PMID: 34850907) |
| Grant Information: | MCRF21011 Victorian Cancer Agency; PD-16-03 National Breast Cancer Foundation; Cancer Australia; Australian Cancer Research Foundation; RSP-358-2020 Tour de Cure |
| Contributed Indexing: | Keywords: ID1; breast cancer; pancreatic cancer; tumour vasculature; vasculogenic mimicry |
| Substance Nomenclature: | 0 (Inhibitor of Differentiation Protein 1); 0 (ID1 protein, human) |
| Entry Date(s): | Date Created: 20250321 Date Completed: 20250910 Latest Revision: 20250912 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12420356 |
| DOI: | 10.1002/1878-0261.70027 |
| PMID: | 40116596 |
| Database: | MEDLINE |
Journal Article